Free evidence reading: kidney, oncology and rare disease
Real sources · Illustrative request · Sample version
Customer question
A clinician explores sources and evidence types across three public topics for free. Frontiers & News offers continued reading; this example uses dated historical sources to illustrate editing.
How does one page distinguish research, regulatory announcements and guidance under revision?
Each card states what changed, whom it concerns, source and date. Do not repackage an older paper as today’s discovery.
Source type and reading use
| Check / stage | Chart content |
|---|---|
| Kidney · guideline status | KDIGO: published 2024 guidance; focused update underway |
| Oncology · study | OPRA: 2024 long-term follow-up and organ-preservation endpoint |
| Rare disease · regulator | FDA: Itvisma approval announcement of 24 Nov 2025 |
An editorial sample using dated historical sources, not a claim of three new developments this week. Updates underway differ from published recommendations.
Analysis excerpt
| Check | Finding / sample content | Use |
|---|---|---|
| Kidney card | Check the guidance version and original studies | Label guidance/update status and retain scan date |
| Oncology card | Explain organ-preservation separately from survival | Label original research and link its report |
| Rare-disease card | The announcement distinguishes product and age criteria | Label regulatory news rather than individual efficacy comparison |
Delivery manifest
| File | Format | Contents |
|---|---|---|
| Three-topic reading sample | PDF / HTML | Three cards with content type, source date and short summary |
| Monthly index example | CSV | Topic, original source, publication date, reading use and open checks |
This is an illustrative formal delivery manifest. This pack supplies an HTML report, CSV tables and a source register. Agree formal formats, quantities and scope in the quote.
Acceptance criteria
- Each item retains sources, dates and type. Historical examples are not today’s discoveries, and public reading is not case-specific advice.
Sources
- KDIGO official CKD guideline hub and focused-update notice
https://kdigo.org/guidelines/ckd-evaluation-and-management/ - OPRA randomized phase II trial: long-term results (JCO, 2024)
https://ascopubs.org/doi/10.1200/JCO.23.01208 - FDA: Itvisma approval and distinction from Zolgensma (24 Nov 2025)
https://www.fda.gov/news-events/press-announcements/fda-approves-gene-therapy-treatment-spinal-muscular-atrophy